These monoclonal antibodies neutralize TNF-α, a pro-inflammatory cytokine essential to IBD pathophysiology, by binding soluble and membrane-bound TNF-α, suppressing downstream inflammatory signaling, reducing pro-inflammatory cytokine release, and inducing apoptosis in activated T cells and macrophages [27,28,29]. This evidence concerns the gene TNF and inflammatory bowel disease.